Tech Company Financing Transactions
Euthymics Bioscience Funding Round
Private investors participated in a $4 million Series A capital raise for Euthymics Bioscience. The round was announced on 3/9/2011.
Transaction Overview
Company Name
Announced On
3/9/2011
Transaction Type
Venture Equity
Amount
$4,000,000
Round
Series A
Investors
Proceeds Purpose
This is an add on to the existing series A. According to Euthymics officials, the new funds will be used to move forward preclinical development of its second product candidate EB-1020, a non-stimulant for adult ADHD (attention deficit/hyperactivity disorder).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Bdwy. 14th Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Euthymics Bioscience, a neuroscience-focused biopharmaceutical company, develops medicines for central nervous system disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Anthony McKinney
Chief Marketing Officer
Katherine Laessig
Browse more venture capital transactions:
Prev: 3/9/2011: Flite venture capital transaction
Next: 3/9/2011: GrubHub venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to document funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs